Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> ALK

ALK

ALK (anaplastic lymphoma kinase) is a member of insulin receptor protein-tyrosine superfamily, functioning in embryonic development and involved in cell survival and cell fate.

Products for  ALK

  1. Cat.No. Product Name Information
  2. GC14729 (R)-Crizotinib A c-MET and ALK receptor tyrosine kinase inhibitor (R)-Crizotinib Chemical Structure
  3. GC13136 (S)-Crizotinib Potent MTH1 inhibitor (S)-Crizotinib Chemical Structure
  4. GC33319 2-Keto Crizotinib (PF-06260182) 2-Keto Crizotinib (PF-06260182) (PF-06260182) is an active lactam metabolite of crizotinib. 2-Keto Crizotinib (PF-06260182) Chemical Structure
  5. GC35280 Alectinib Hydrochloride Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration. Alectinib Hydrochloride Chemical Structure
  6. GC35287 ALK inhibitor 1 ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=31 nM) and focal adhesion kinase (FAK; IC50=2 nM). ALK inhibitor 1 Chemical Structure
  7. GC17376 ALK inhibitor 2 An inhibitor of TSSK2 ALK inhibitor 2 Chemical Structure
  8. GC63387 ALK kinase inhibitor-1 ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202. ALK kinase inhibitor-1 Chemical Structure
  9. GC35289 ALK-IN-5 ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK), with an IC50 of 2.9 nM. ALK-IN-5 Chemical Structure
  10. GC35290 ALK-IN-6 ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC50 values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively. ALK-IN-6 Chemical Structure
  11. GC17283 AP26113 AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113 Chemical Structure
  12. GC14446 ASP3026 An ALK inhibitor ASP3026 Chemical Structure
  13. GC14189 AZD-3463 ALK/IGF1R inhibitor AZD-3463 Chemical Structure
  14. GC19063 Belizatinib Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase. Belizatinib Chemical Structure
  15. GC19084 Brigatinib A highly potent and selective ALK inhibitor Brigatinib Chemical Structure
  16. GC15145 CEP-28122 anaplastic lymphoma kinase (ALK) inhibitor CEP-28122 Chemical Structure
  17. GC35652 CEP-28122 mesylate salt CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt Chemical Structure
  18. GC15273 CEP-37440 FAK/ALK inhibitor,potent and selective CEP-37440 Chemical Structure
  19. GC45789 Ceritinib-d7 An internal standard for the quantification of ceritinib Ceritinib-d7 Chemical Structure
  20. GC16025 CH5424802 CH5424802 (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. CH5424802 demonstrates effective central nervous system (CNS) penetration. CH5424802 Chemical Structure
  21. GC12616 Crizotinib hydrochloride

    inhibitor of the c-Met kinase and the NPM-ALK

     Crizotinib hydrochloride Chemical Structure
  22. GC14298 DMH-1 Selective BMP ALK2 receptor DMH-1 Chemical Structure
  23. GC33190 Ensartinib (X-396) Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib (X-396) Chemical Structure
  24. GC32864 Ensartinib hydrochloride (X-396 hydrochloride) Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib hydrochloride (X-396 hydrochloride) Chemical Structure
  25. GC14476 Entrectinib Orally active inhibitor of ALK kinase Entrectinib Chemical Structure
  26. GC65380 Envonalkib Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer. Envonalkib Chemical Structure
  27. GC36021 F-1 F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1 Chemical Structure
  28. GC12273 GSK1838705A IGF-IR/IR/ALK inhibitor, ATP-competitive GSK1838705A Chemical Structure
  29. GC36222 HG-14-10-04 An ALK inhibitor HG-14-10-04 Chemical Structure
  30. GC33062 JH-VIII-157-02 JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. JH-VIII-157-02 Chemical Structure
  31. GC13902 KRCA 0008 Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor KRCA 0008 Chemical Structure
  32. GC14552 LDK378 LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. LDK378 Chemical Structure
  33. GC17452 LDK378 dihydrochloride LDK378 dihydrochloride Chemical Structure
  34. GC50327 LDN 193189 dihydrochloride Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs LDN 193189 dihydrochloride Chemical Structure
  35. GC16580 LDN-193189 ALK inhibitor,potent and selective LDN-193189 Chemical Structure
  36. GC17035 LDN-212854 BMP receptor inhibitor,potent and selective LDN-212854 Chemical Structure
  37. GC13225 LDN-214117 potent and selective ALK2 inhibitor LDN-214117 Chemical Structure
  38. GC14931 LDN193189 Hydrochloride An inhibitor of BMP receptors ALK1, ALK2, ALK3, and ALK6 LDN193189 Hydrochloride Chemical Structure
  39. GC17582 ML347 BMP receptor inhibitor,potent and selective ML347 Chemical Structure
  40. GC65243 MS4077 MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK. MS4077 Chemical Structure
  41. GC64966 MS4078 MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK. MS4078 Chemical Structure
  42. GC14794 PF-06463922 PF-06463922 (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor. PF-06463922 has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALKL1196M, respectively. PF-06463922 has anticancer activity. PF-06463922 Chemical Structure
  43. GC19362 Repotrectinib TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively. Repotrectinib Chemical Structure
  44. GC48070 SB-431542 (hydrate) Inhibitor of receptors ALK4, ALK5, and ALK7 SB-431542 (hydrate) Chemical Structure
  45. GC14349 SB525334 (TGF-beta1) receptor inhibitor SB525334 Chemical Structure
  46. GC44903 SMAD3 Inhibitor, SIS3 SMAD3 Inhibitor, SIS3 is a potent and selective inhibitor of Smad3 phosphorylation. SMAD3 Inhibitor, SIS3 Chemical Structure
  47. GC16694 TAE684 (NVP-TAE684) A selective ALK inhibitor TAE684 (NVP-TAE684) Chemical Structure
  48. GC50562 TL 13-110 Negative control for TL 13-112 TL 13-110 Chemical Structure
  49. GC50563 TL 13-22 Negative control for TL 13-12 TL 13-22 Chemical Structure
  50. GC62260 TPX-0131 TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). TPX-0131 has strong antitumor activities. TPX-0131 Chemical Structure
  51. GC62516 UNC5293 UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research. UNC5293 Chemical Structure
  52. GC19140 X-376 X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively. X-376 Chemical Structure
  53. GC62146 XST-14 XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects. XST-14 Chemical Structure
  54. GC64013 ZX-29 ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect. ZX-29 Chemical Structure

53 Item(s)

per page

Set Descending Direction